Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell Lymphoma
Staying abreast of recent clinical practice guidelines for the management of relapsed/refractory mantle cell lymphoma can be challenging for providers who may seldom encounter it in community practice. In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.
"Fortunately, treatments such as BTK inhibitors…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.